|
BioSyntech is a development-stage company specializing in the creation and development of biotherapeutic thermogels to be used for human tissue repair and therapeutic delivery. The BST-Gels are liquid at room temperature but solidify at human body temperature, and they are classified as medical devices by the FDA and other regulators. Various products in development include BST-CarGel (cartilage repair), BST-InPod (heel cushioning), and BST-DermOn (chronic wound healing). For now, the company makes its money primarily from the sale of Ultrasan, a pure form of chitosan (derived from chitin and is also used in the thermogels), and providing analytical services to support Ultrasan.
|
| | | Contact Information | |
Address: |
475 Armand-Frappier Blvd.
Laval, Quebec H7V 4B3, Canada
| | Phone: | 450-686-2437 | | Fax: | 450-686-8952 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2008): | 0.30 M | | Revenue Growth (1 yr): | 26.90% | | Employees (2007): | 45 | | Employee Growth (1 yr): | 66.70% |
|
|
Key People
| | • |
Chairman:
André Archimbaud
| | • |
CEO and Director:
Jeanne M. Bertonis
| | • |
CFO:
Antoinette Lizzi
|
|
|
